mercaptoethanol and Cancer of Ovary
mercaptoethanol has been researched along with Cancer of Ovary in 11 studies
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy." | 9.06 | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989) |
"Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy." | 5.06 | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989) |
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
"A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion." | 1.28 | Severe renal failure following high-dose ifosfamide and mesna. ( de Jong, PE; Elema, JD; Mulder, NH; Willemse, PH, 1989) |
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989) |
Research
Studies (11)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (63.64) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors
Authors | Studies |
---|---|
Yan, F | 1 |
Ha, JH | 1 |
Yan, Y | 1 |
Ton, SB | 1 |
Wang, C | 1 |
Mutembei, B | 1 |
Alhajeri, ZA | 1 |
McNiel, AF | 1 |
Keddissi, AJ | 1 |
Zhang, Q | 1 |
Jayaraman, M | 1 |
Dhanasekaran, DN | 1 |
Tang, Q | 1 |
D'Hollander, A | 1 |
Jans, H | 1 |
Velde, GV | 1 |
Verstraete, C | 1 |
Massa, S | 1 |
Devoogdt, N | 1 |
Stakenborg, T | 1 |
Muyldermans, S | 1 |
Lagae, L | 1 |
Himmelreich, U | 1 |
Burkert, H | 1 |
Schnitker, J | 1 |
Fichtner, E | 1 |
Willemse, PH | 2 |
vd Burg, ME | 1 |
vd Gaast, A | 1 |
Neijt, JP | 1 |
ten Bokkel Huinink, WW | 1 |
Aalders, JG | 1 |
de Vries, EG | 1 |
Sutton, GP | 3 |
Blessing, JA | 3 |
Photopulos, G | 2 |
Berman, ML | 3 |
Homesley, HD | 3 |
de Jong, PE | 1 |
Elema, JD | 1 |
Mulder, NH | 1 |
Malfetano, J | 1 |
Li, GC | 1 |
Brock, N | 1 |
Li, JQ | 1 |
Guan, ZZ | 1 |
He, YJ | 1 |
Fuller, GM | 1 |
Rasco, MA | 1 |
McCombs, ML | 1 |
Barnett, DR | 1 |
Bowman, BH | 1 |
Black, JA | 1 |
Chan, GF | 1 |
Hew, CL | 1 |
Dixon, GH | 1 |
Trials
1 trial available for mercaptoethanol and Cancer of Ovary
Article | Year |
---|---|
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Leukocyte Count; Mercaptoethanol; Mesna; Mul | 1989 |
Other Studies
10 other studies available for mercaptoethanol and Cancer of Ovary
Article | Year |
---|---|
Optical Coherence Tomography of Tumor Spheroids Identifies Candidates for Drug Repurposing in Ovarian Cancer.
Topics: Drug Repositioning; Female; Humans; Mercaptoethanol; Ovarian Neoplasms; Tomography, Optical Coherenc | 2023 |
Limiting the protein corona: A successful strategy for in vivo active targeting of anti-HER2 nanobody-functionalized nanostars.
Topics: Animals; Cell Line, Tumor; CHO Cells; Cricetulus; Drug Delivery Systems; Female; Gold; Humans; Merca | 2017 |
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Topics: Adolescent; Adult; Aged; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Gastrointestinal Dise | 1979 |
Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Infusions, Intravenous; | 1990 |
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesn | 1990 |
Severe renal failure following high-dose ifosfamide and mesna.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma; Dose-Respons | 1989 |
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 1989 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Subunit composition of haptoglobin 2-2 polymers.
Topics: Amino Acids; Ascitic Fluid; Disulfides; Electrophoresis, Polyacrylamide Gel; Female; Haptoglobins; H | 1973 |
Gene action in the human haptoglobins. 3. Isolation of the alpha-chains as single gene products. Isolation, molecular weight, and amino acid composition of alpha and beta chains.
Topics: Acetamides; Alkylation; Amino Acids; Anhydrides; Ascitic Fluid; Carcinoma; Chemical Phenomena; Chemi | 1970 |